211 related articles for article (PubMed ID: 30417471)
1. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis.
Qu D; Cui F; Lu D; Yang Y; Xu Y
Cancer Sci; 2019 Jan; 110(1):157-165. PubMed ID: 30417471
[TBL] [Abstract][Full Text] [Related]
2. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway.
Guo W; Li H; Liu H; Ma X; Yang S; Wang Z
Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256
[TBL] [Abstract][Full Text] [Related]
3. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
Wu HT; Xie CR; Lv J; Qi HQ; Wang F; Zhang S; Fang QL; Wang FQ; Lu YY; Yin ZY
Lab Invest; 2018 Aug; 98(8):1014-1024. PubMed ID: 29785050
[TBL] [Abstract][Full Text] [Related]
5. Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression.
Tian C; Abudoureyimu M; Lin X; Chu X; Wang R
Cell Death Dis; 2021 Nov; 12(11):1047. PubMed ID: 34741030
[TBL] [Abstract][Full Text] [Related]
6. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma.
Amisaki M; Yagyu T; Uchinaka EI; Morimoto M; Hanaki T; Watanabe J; Tokuyasu N; Sakamoto T; Honjo S; Fujiwara Y
Anticancer Res; 2019 Aug; 39(8):4423-4430. PubMed ID: 31366540
[TBL] [Abstract][Full Text] [Related]
8. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
[TBL] [Abstract][Full Text] [Related]
9. DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma.
Yuan SG; Liao WJ; Yang JJ; Huang GJ; Huang ZQ
Asian Pac J Cancer Prev; 2014; 15(24):10917-22. PubMed ID: 25605201
[TBL] [Abstract][Full Text] [Related]
10. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells.
Kikuchi R; Sampetrean O; Saya H; Yoshida K; Toda M
J Neurooncol; 2017 Jun; 133(2):297-307. PubMed ID: 28555424
[TBL] [Abstract][Full Text] [Related]
12. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.
Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
Cancer Lett; 2018 Feb; 414():71-80. PubMed ID: 29126912
[TBL] [Abstract][Full Text] [Related]
13. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
Yu J; Xu QG; Wang ZG; Yang Y; Zhang L; Ma JZ; Sun SH; Yang F; Zhou WP
J Hepatol; 2018 Jun; 68(6):1214-1227. PubMed ID: 29378234
[TBL] [Abstract][Full Text] [Related]
15. DEP Domain Containing 1 Promotes Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Colorectal Cancer by Enhancing Expression of Suppressor of Zest 12.
Wang Q; Jiang S; Liu J; Ma G; Zheng J; Zhang Y
Cancer Biother Radiopharm; 2021 Feb; 36(1):36-44. PubMed ID: 32343606
[No Abstract] [Full Text] [Related]
16. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
17. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
Zhang N; Chen X
Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
[TBL] [Abstract][Full Text] [Related]
18. RICH2, a potential tumor suppressor in hepatocellular carcinoma.
Zhang J; Yang C; Gong L; Zhu S; Tian J; Zhang F; Zhu Q; Wang J; Lan M; Li Y; Zhang W
Front Biosci (Landmark Ed); 2019 Jun; 24(8):1363-1376. PubMed ID: 31136984
[TBL] [Abstract][Full Text] [Related]
19. DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer.
Huang L; Chen K; Cai ZP; Chen FC; Shen HY; Zhao WH; Yang SJ; Chen XB; Tang GX; Lin X
Biochem Biophys Res Commun; 2017 Aug; 490(3):707-712. PubMed ID: 28634077
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA.
Pan Y; Qin T; Yin S; Zhang X; Gao X; Mu L
Biomed Pharmacother; 2017 Mar; 87():669-677. PubMed ID: 28088733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
